Reimbursement

Biotech Report: Ultra Man

Biotech Report: Ultra Man

By

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

Study says CME leads to million-dollar savings

By

The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.

Orexigen, Vivus remain in weight-loss limbo

By

Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.

Oncology lifts Roche's Q1, Lucentis finds new fans

Oncology lifts Roche's Q1, Lucentis finds new fans

By

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.

Docs' presidential preferences follow practice type

Docs' presidential preferences follow practice type

By

Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians' presidential preferences.

Email Newsletters